skip to primary navigationskip to content
Home

Cambridge Immunology Network

Studying at Cambridge

 

Dr Edward Banham-Hall

Dr Edward Banham-Hall

Download as vCard

Research Interests

Dr Edward Banham-Hall studied the role of the p110delta isoform of PI3 kinase in immune responses to Streptococcus pneumoniae sepsis for his PhD in the Okkenhaug laboratory at The Babraham Institute.  During the course of these studies he took a leading role in the discovery of a novel cause of Primary Immunodeficiency called Activated PI3kinase Delta Syndrome, or APDS.  Affected patients demonstrate significant susceptibility to infection with encapsulated organisms, such as S. pneumoniae, and frequently die of complications of their illness either in childhood or early adulthood.
After completing his PhD Dr Banham-Hall returned temporarily to full time clinical medicine in the NHS before taking up a substantive consultant post at Addenbrookes Hospital with a secondment to GSK to work in experimental medicine.  He now combines regular sessions undertaking clinical medicine with participating in the design, conduct and analysis of phase 1 and 2a clinical trials for a variety of conditions, including Primary Immunodeficiency.
In his spare time Dr Banham-Hall works on projects that combine digital breakthroughs with clinical and biological opportunities.  His latest project in this respect is the technical development of an educational website for postgraduate medical training, Clinical Skills Pro.

Keywords

PI3K regulation ; PI3K

Topics

  • sepsis
  • autoimmunity
  • Primary Immunodeficiency
  • Activated PI3kinase Delta Syndrome

Key Publications

Banham-Hall E1, Clatworthy MR, Okkenhaug K. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatol J. 2012;6:245-58. doi: 10.2174/1874312901206010245. Epub 2012 Sep 7.

Angulo I*, Vadas O*, Garçon F*, Banham-Hall E*, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O, Smyth D, Maes M, Fiddler C, Juss J, Cilliers D, Markelj G, Chandra A, Farmer G, Kielkowska A, Clark J, Kracker S, Debré M, Picard C, Pellier I, Jabado N, Morris JA, Barcenas-Morales G, Fischer A, Stephens L, Hawkins P, Barrett JC, Abinun M, Clatworthy M, Durandy A, Doffinger R, Chilvers E, Cant AJ, Kumararatne D, Okkenhaug K, Williams RL, Condliffe A, Nejentsev S. Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage. Science. 2013 Oct 22. *shared first authors

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Banham-Hall E, Clatworthy MR, Okkenhaug K. Open Rheumatol J. 2012;6:245-58.

Study at Cambridge

About the University

Research at Cambridge